MSF Hits Back At ViiV Over ‘Infuriating’ Cabotegravir Approach
Welcomes MPP Deal For Generics, But Calls For More Transparency From Originator
In the wake of a licensing deal with the MPP that will see three generics firms produce versions of ViiV’s long-acting cabotegravir for lower-income countries, Médecins Sans Frontières has urged the originator to be more transparent about plans to distribute the HIV prevention medicine in high-burden territories.
